IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA (NCT02451748), a non-randomized phase 4 study. The primary outcome is IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells of RA Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA..

2. Clinical Question

The study’s stated purpose is to examine factors in cells associated with inflamed joints that may be relevant to rheumatoid arthritis. Its primary outcome concerns expression of IL-7 and IL-7R mRNA measured by real-time RT-PCR, expressed as fold change versus a housekeeping gene change. The record names active versus inactive disease and treatment with DMARDs and/or Cimzia in the outcome title. It does not report the observed expression values or define a complete comparison of disease activity for each measurement occasion.

Accordingly, the registry record frames a biological measurement question, not a randomized estimate of treatment effect. The groups differ in treatment and response status, and their assignment was not randomized. Any observed difference in expression, if reported elsewhere, would need to be interpreted in light of those design features and the small outcome populations recorded for follow-up.

3. Trial Design

This completed phase 4 study is listed as non-randomized, unmasked, and sequential, with rheumatoid arthritis as its condition and enrollment of 32. The University of Illinois Chicago is named as sponsor. The record gives a start date of 2015-08 and primary completion of 2017-09.

The registry describes two groups. One is titled “DMARD's Responder and Non-Responder”; its description refers to people receiving DMARDs and achieving remission, defined there as DAS28<2.6, with blood sampling. The other is titled “DMARD's plus Cimzia (Certolizumab pegol)” and is described as including people who did not respond to DMARDs and then received DMARDs as well as Cimzia, with blood sampling at the onset of the study and 3 and 6 months later.

The group descriptions refer to (50) and (150) subjects, respectively, while overall enrollment is listed as 32. The record does not reconcile these figures, so the group-description counts should not be read as the number enrolled or analyzed. For the primary outcome, the recorded population is 10 at 3 months and 5 at 6 months in the DMARDs plus Cimzia group.

Because allocation was non-randomized, the groups are not a like-for-like control comparison. Treatment, response status, and disease activity may distinguish the groups, but the registry record does not report enough detail to assess those factors participant by participant. The model is listed as sequential; further details of the sequence and enrollment process are not reported in the registry record. Masking is listed as none. The record does not report a protocol-level explanation of allocation, masking, or group construction.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: 10 at 3 months, 5 at 6 months for DMARD's plus Cimzia group

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells of RA Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA., measured over baseline and 3 and 6 months.

The primary endpoint measures IL-7 and IL-7R mRNA expression in peripheral blood mononuclear cells of people with rheumatoid arthritis. The registry says expression was measured using real-time RT-PCR and expressed as fold change versus housekeeping gene change. It lists a mean as the summary measure and standard error as the dispersion, with measurements at baseline, 3 months, and 6 months.

As a biological endpoint, gene expression can describe molecular activity in the sampled cells. A housekeeping gene is used as a reference in expression measurement; the reported fold-change scale is intended to express the target measurement relative to that reference. The registry does not provide further assay details, definitions of the calculated fold change, or a threshold for interpreting a difference as meaningful.

Repeated measurements can describe how expression changes over time within a group, while a comparison between groups can describe how their measured expression differs. These are distinct questions. The endpoint title refers to active versus inactive disease and DMARD and/or Cimzia treatment, but the posted record does not provide outcome values, specific contrasts, or a complete analysis description. Therefore, it is not possible to describe the direction, magnitude, or precision of any expression result from this record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does the endpoint summary mean? The primary measure is continuous: it is a numerical expression measurement, summarized in the registry as a mean. A mean describes the average of the measurements included in an analysis. It does not show how widely individual measurements vary, whether the values are skewed, or whether a small number of observations strongly influence the average. The endpoint is described as fold change versus housekeeping gene change, measured by real-time RT-PCR. The registry does not provide the underlying values or a fuller account of the calculation.

The record lists standard error as the measure of dispersion. In general, a standard error describes the uncertainty of an estimated summary, such as a mean, rather than the spread of individual observations. It can contribute to an interval estimate or test of a hypothesis, but it is not interchangeable with a standard deviation. Without the reported mean and standard error, neither the estimated expression level nor its precision can be read from this registry record.

How should repeated measurements be understood? Measurements are listed at baseline, 3 months, and 6 months. In general, repeated measurements from the same participant are related: a person’s values over time are not necessarily independent observations. An analysis of change over time should account for that within-person relationship. The registry does not report whether the same participants contributed measurements at each time, what statistical model was used, or whether the analysis compared changes, time-specific means, or both. It is therefore not possible to assign a particular repeated-measures method to this study.

The primary outcome population is stated as 10 at 3 months and 5 at 6 months in the DMARDs plus Cimzia group. These counts do not by themselves establish a complete repeated-measures dataset. For example, the record does not specify how many of those participants had baseline measurements, whether any measurements were excluded, or how missing observations were handled. No particular explanation for the differing counts should be inferred.

What does non-randomized allocation imply? As a general statistical matter, random allocation can help balance known and unknown characteristics between groups on average. In a non-randomized study, group membership may be associated with baseline characteristics, disease activity, or treatment history. A raw difference in expression can therefore combine the association of interest with differences between the groups. Statistical adjustment can sometimes address measured characteristics, but cannot guarantee removal of all confounding. The registry record does not report an adjustment model or covariates, so no claim about adjustment can be made.

The record labels the study model sequential and masking none. Those labels describe aspects of design but do not specify the exact sequence, the assessment procedures, or the statistical methods. Further details are not reported in the registry record. The listed intervention set includes lab work and several medications, but the record does not connect every listed medication to a specific participant or analysis.

How should hypothesis tests and intervals be read? In general, a p-value describes how compatible data are with a specified null hypothesis under the assumptions of a statistical test. It does not measure the size or practical importance of an effect, and it does not give the probability that a hypothesis is true. A confidence interval gives a range of estimates compatible with the data and the method used; its width conveys statistical precision. Neither p-values nor confidence intervals for the primary outcome are reported in the registry record.

The record lists six analyses, but does not state the hypotheses, tests, model terms, significance threshold, or whether results were adjusted. It is therefore not possible to determine how any analysis would account for the repeated time points, multiple expression targets, or group comparisons. The record also does not report a statistical analysis plan, interim analyses, or a sample-size justification. No specific model or inferential procedure should be attributed to the study.

Why do sample size and variability matter? In general, estimates based on fewer observations tend to be less precise, although precision also depends on variability and the design. A small outcome population can make it difficult to distinguish a real pattern from sampling variation. The listed counts at 3 months and 6 months provide context, but no observed outcome variability or effect estimate is available to assess the precision of a result. The enrollment count cannot substitute for the number of people contributing data to a particular endpoint or time point.

General statistical considerations do not supply missing trial results. Without the outcome values, analysis definitions, and missing-data details, the appropriate interpretation is limited to what the registry explicitly records: the intended continuous molecular endpoint, its stated time points and summary measure, the non-randomized design, and the small reported follow-up populations for the DMARDs plus Cimzia group.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists one outcome measure and six analyses. It does not describe the six analyses, identify which comparisons they represent, or state whether each was prespecified. It also does not report a multiplicity procedure or explain how the interpretation of multiple tests was handled. The number of listed analyses alone is not enough to determine the family of hypotheses or the risk of chance findings.

As a general statistical concept, multiplicity arises when several hypotheses are tested or several outcomes and time points are examined. Repeated testing can increase the chance that at least one result appears notable by chance. Methods for addressing multiplicity depend on the questions and analysis plan. Because the registry record does not report that plan or the analysis results, it is not possible to say whether any adjustment was used or what conclusions would follow from it.

The record reports 10 participants at 3 months and 5 at 6 months for the DMARDs plus Cimzia group. It does not describe missing measurements, reasons for missingness, exclusions, or the method used to include participants with incomplete follow-up. It also does not state whether analyses used all available observations or a defined analysis population. Those details are not reported in the registry record.

In general, missing-data methods rely on assumptions about why values are absent. Different assumptions can lead to different estimates, especially when follow-up numbers are limited. The available counts do not establish why follow-up populations differ and should not be used to infer dropout or another cause. The registry does not report an intention-to-treat population, a per-protocol population, or another formal analysis population definition. As a result, the target population for any primary estimate cannot be determined from the record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry reports two safety groups. In the “DMARD's Responder and Non-Responder” group, 12 participants were at risk for serious adverse events and none were recorded as affected; 12 were at risk for other adverse events and none were recorded as affected. In the “DMARD's Plus Cimzia (Certolizumab Pegol)” group, 15 were at risk for serious adverse events and none were recorded as affected; 15 were at risk for other adverse events and none were recorded as affected. The record also lists zero deaths in each group and no top serious adverse-event terms.

These are event counts and at-risk counts as recorded, not estimates of comparative safety. The figures do not establish that no adverse events occurred outside the recorded groups or observation period. The registry record does not explain how the safety populations were selected, how long participants were followed for safety, or how events were defined and collected. The at-risk counts also do not match overall enrollment, and the reason is not reported.

In general, observing no events in a limited group does not establish that the underlying event risk is zero. The counts should be read narrowly as the posted safety results, without extrapolating to other populations or treatments.

12. What the Result Does, and Does Not, Mean

The registry record describes a study of IL-7 and IL-7R mRNA expression in peripheral blood mononuclear cells among people with rheumatoid arthritis. It identifies real-time RT-PCR as the measurement method, names baseline, 3 months, and 6 months as time points, and states that the primary measure is a mean with standard error. It also records a non-randomized, unmasked, sequential design and gives the outcome population at later time points for the DMARDs plus Cimzia group.

Those design details explain what the study intended to examine, but the record does not include the primary outcome measurements or statistical estimates. No expression pattern, difference between groups, change over time, or uncertainty can be described from the posted results. The record also does not report a statistical analysis plan or enough information to determine how the listed analyses were conducted.

Even if numerical expression results were available, a non-randomized comparison would not by itself establish that treatment caused an observed difference. As a general consideration, groups defined by treatment and response can differ in ways that also relate to gene expression. The registry record does not report enough participant-level or analytic detail to evaluate those possible explanations.

The molecular endpoint is not, on its own, a measure of symptoms, function, or clinical benefit. The registry’s stated purpose is to better understand cellular factors related to rheumatoid arthritis; it does not report a clinical outcome result that would establish a patient-level effect. The posted safety counts are also limited: no serious adverse events, other adverse events, or deaths are listed for the reported at-risk groups, but those figures do not establish the absence of risk.

The defensible conclusion is therefore about the scope and limits of the registry entry: it records a biological study question and some design and safety information, while leaving the primary expression results and key analysis details unreported.

13. Why This Trial Matters Statistically

This study is statistically notable as a registry record in which the biological question is more fully stated than the results available for interpretation. It identifies IL-7 and IL-7R expression as the focus, specifies peripheral blood mononuclear cells and real-time RT-PCR, and names multiple measurement occasions. Yet it does not report the primary outcome values, their standard errors, or estimates of change or group difference. Without those quantities, the central statistical question cannot be answered from the record.

The non-randomized design is important because the groups are described in relation to DMARD response and subsequent treatment. As a general principle, group differences in observational or non-randomized comparisons can reflect participant characteristics as well as treatment. The registry does not provide an adjustment strategy that would clarify how this issue was handled. Calling the groups treatment arms should not obscure that they are not a randomized control comparison.

The mismatch between overall enrollment of 32 and the group descriptions referring to (50) and (150) subjects is also relevant to interpretation. The record does not reconcile those figures. Meanwhile, the primary outcome population is listed as 10 at 3 months and 5 at 6 months for the DMARDs plus Cimzia group. Distinguishing planned group descriptions, enrollment, and endpoint-specific populations is essential for understanding what a reported estimate would represent.

Finally, six analyses are listed without details, and information about missing observations, analysis populations, multiplicity, and the statistical plan is not reported in the registry record. These omissions prevent a careful assessment of statistical uncertainty and selective interpretation. The record therefore illustrates why design labels and a stated endpoint are not substitutes for analyzable results and a transparent account of the analysis.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting this study is that the registry record does not report the primary expression results. Means, standard errors, effect estimates, confidence intervals, and p-values are absent, so neither the direction nor precision of the outcome can be assessed. The record states that six analyses were conducted or listed but does not describe their questions or methods.

The design is non-randomized and unmasked. The two groups are described through DMARD response and treatment, so they do not constitute a like-for-like control comparison. The registry does not report an adjustment strategy or sufficient detail to evaluate whether group differences were accounted for.

Enrollment is listed as 32, while the arm descriptions refer to (50) and (150) subjects. The record does not reconcile those counts. The primary outcome population is reported as 10 at 3 months and 5 at 6 months in the DMARDs plus Cimzia group, but the registry does not provide corresponding population counts for the other group or explain the changing follow-up counts. Reasons for missing measurements and the handling of incomplete data are not reported.

The entry does not report a sample-size justification, detailed analysis plan, multiplicity approach, or formal analysis-population definitions. It also does not provide enough assay detail to assess how the fold-change measure was derived. The safety denominators are smaller than overall enrollment, and their selection and observation period are not explained. These limitations restrict what can be concluded from the registry record, independently of any results that may exist elsewhere.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA — NCT02451748.
• Registry record last updated 2024-07-10; status last verified 2024-07.
• Results first posted 2024-07-10.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

This completed phase 4 study of rheumatoid arthritis is listed as non-randomized, unmasked, and sequential, with enrollment of 32. The sponsor is the University of Illinois Chicago. The registry describes a DMARD responder and non-responder group and a group receiving DMARDs plus Cimzia.

The primary endpoint is IL-7 and IL-7R mRNA expression in peripheral blood mononuclear cells, measured by real-time RT-PCR and summarized as a mean with standard error at baseline, 3 months, and 6 months. The listed outcome population in the DMARDs plus Cimzia group is 10 at 3 months and 5 at 6 months. Primary outcome values and analysis details are not reported in the registry record.

Safety results list zero serious adverse events, zero other adverse events, and zero deaths in each group, with 12 and 15 participants at risk, respectively. The record does not explain the difference between overall enrollment and the counts in the group descriptions or safety populations.